Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvalin (cathine hydrochloride) vs placebo in obese patients (BMI 30–45)
DRKS00005184Phase 3Recruiting
- Sponsor
- RIEMSER
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Placebo (Alvalin placebo) + basal therapy with Alvalin (cathine hydrochloride) intermittent + basal therapy (2 arms). Started Aug 2013; status: recruiting.
02
Drugs
cathine
03
Conditions
obesity
Beyond the preview
Go deeper on DRKS00005184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005184.